Postmarket Data Tops FDA’s Research Wish List In Safety Self-Assessment
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry must weigh value of strengthening agency’s armamentarium as FDA continues to seek outside collaborations in follow-up to 2011 publication.
You may also be interested in...
Whose Burden Is It Anyway? REMS’ Health Care Impact Belongs To FDA, PhRMA Says
Industry group contends that FDA should assess whether a REMS places an undue burden on the health care industry – because asking companies to do that evaluation would be an additional burden on the health care system.
Regulatory Science Next To Be Outsourced?
CDER report calls for broader partnerships with outside bodies in regulatory science.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.